Reversal of P-glycoprotein is greatly reduced by the presence of plasma but can be monitored by an ex vivo clinical assay

Anti-Cancer Drugs

Volumn 7, Issue 6, 1996, Pages 678-686

  Ayesh, Suhail ^a   Lyubimov, Elena ^a   Algour, Nurit ^b   Stein, Wilfred D ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Ex vivo assay; Multidrug resistance; P glycoprotein; Plasma

Indexed keywords

AMIODARONE; CYCLOSPORIN A; DAUNORUBICIN; DIPYRIDAMOLE; GLYCOPROTEIN P; MEFLOQUINE; PROCHLORPERAZINE; PROPAFENONE; QUINIDINE; TAMOXIFEN; VINBLASTINE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; LEUKEMIA P 388; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PLASMA; PRIORITY JOURNAL;

ANIMALS; CYCLOSPORINE; DAUNORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; KIDNEY; LEUKEMIA P388; MICE; P-GLYCOPROTEIN; PLASMA; QUINIDINE; VERAPAMIL; VINBLASTINE;

EID: 0029960485     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199608000-00009     Document Type: Article

References (26)

1. Schinkel AH, Borst P. Multidrug resistance mediated by P-glycoprotein. Cancer Biol 1991; 2: 213-26.
2. Tang-Wai DF, Kajiji S, DiCapua F, de Graaf D, Roninson IB, Gros P. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 1995; 34: 32-9.
3. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992; 31: 205-13.
4. Twentyman PR. MDR1 (P-glycoprotein) gene expression - implications for resistance modifier trials [editorial; comment]. J Natl Cancer Inst 1992; 84: 1458-60.
5. Raderer M, Scheithauer W Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 1993; 72: 3553-63.
6. Twentyman PR, Rhodes T, Rayner S. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 1994; 30A: 1360-9.
7. Mulder HS, Lankelma J, Dekker H, Broxterman HJ, Pinedo HM. Daunorubicin efflux against a concentration gradient in non-P-glycoprotein multidrug-resistant lung-cancer cells. Int J Cancer 1994; 59: 275-81.
8. Breuninger LM, Paul S, Gaughan K, et al. Expression of multidrug-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 1995; 55: 5342-7.
9. Almquist KC, Loe DW, Hipfner DR, Mackie JE, Cole SP, Deeley RG. Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res 1995; 55: 102-10.
10. Hill BT, Vandergraaf WTA, Hosking LK, Devries EGE, Mulder NH, Whelan RDH. Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro. Int J Cancer 1993; 55: 330-7.
11. Campling BG, Baer K, Baker HM, Lam YM, Cole SPC. Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer cell lines. Br J Cancer 1993; 68: 327-35.
12. Mattern J, Volm M. Multiple pathway drug resistance (review). Int J Oncol 1993; 2: 557-61.
13. Kirk J, Houlbrook S, Stuart NS, Stratford J, Harris AL, Carmichael J. Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites. Eur J Cancer 1993; 29: 1152-7.
14. Leyland-Jones B, Dalton W, Fisher GA, Sikic BI. Reversal of multidrug resistance to cancer chemotherapy. Cancer 1993; 72: 3484-8.
15. List AF. Preclinical investigations of drug resistance. Curr Opin Oncol 1995; 7: 19-27.
16. Miller RL, Bukowski RM, Budd GT, et al. Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial. J Clin Oncol 1988; 6: 880-888.
17. Wishart GC, Plumb JA, Morrison JG, Hamilton TG, Kaye SB. Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo. Eur J Cancer 1992; 28: 28-31.
18. Samuels BL, Mick R, Vogelzang NJ, et al. Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther 1993; 54: 421-9.
19. Christen RD, McClay EE Plaxe SC, et al. Phase I/ pharmacokinetic study of high-dose progesterone and doxorubicin J Clin Oncol 1993; 11: 2417-26.
20. Lum BL, Fisher GA, Brophy NA, et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 1993; 72: 3502-14.
21. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol/Oncol Clin N Am 1995; 9: 363-82.
22. Broxterman HJ, Kuiper CM, Schuurhuis GJ, van der Hoeven JJ, Pinedo HM, Lankelma J. Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: role of protein binding. Cancer Lett 1987; 35: 87-95.
23. Ludescher C, Eisterer W, Hilbe W, Hofmann J, Thaler J. Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Br J Haematol 1995; 91: 652-7.
24. Soudon J, Berlion M, Lucas C, Hadda P, Bizzari JP, Calvo F. In vitro activity of S9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells - reversal of multidrug resistance by sera from phase I-treated patients. Cancer Chemother Pharmacol 1995; 36: 195-203.
25. Lyubimov E, Lan L-B, Pashinsky I, Stein WD. Effect of modulators of the multidrug resistance pump on the distribution of vinblastine in tissues of the mouse. Anti-cancer Drugs 1996; 7: 60-9.
26. Lan L-B, Ayesh S, Lyubimov E, Pashinsky I, Stein WD. Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing. Cancer Chemother Pharmacol 1996, 38: 181-90.